Pierre Fab­ry forges I/O dis­cov­ery pact; Ac­tini­um surges on CHMP sup­port

→ France’s Pierre Fab­re struck a deal with H-Im­mune SAS to de­vel­op new im­munother­a­pies, uti­liz­ing H-Im­mune’s tech­nol­o­gy plat­form to gen­er­ate lead can­di­dates of ful­ly hu­man …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.